Document oD0n8jNymbxZ5w0kM079Bajwg

i 3M Gieneral Oftfices gHQ- OfOl - O i l 5 May 15,2001 3M Center St. Paul, MN 55144-1000 612 733 1110 /liiLAaS- i o / S Document Processing Center (7407) ATTN: Section 8(e) Coordinator Office of Pollution, Prevention and Toxics US Environmental Protection Agency 401 M Street, SW Washington, D.C. 20460 i .-;'. ; i a rV* i Hi 4 > t f p ' 2>e>' 3 ? ^ CB/ Re: TSCA 8(e) Supplemental notice for Sulfonate-based and Carboxylic-based Fluorochemicals-Docket numbers 8EHQ-1180-373; 8EHQ-1180-374; 8EHQ-0381-0394; 8EHQ-0598-373 Dear Docket Coordinator: 3M recently completed analyses of several fluorochemical compounds in individual, stored human sera. We have previously reported results of perfluorooctane sulfonate for human sera from pooled samples/1' 21 In the current analyses, individual samples were measured for sulfonate-based and carboxylic-based compounds. Table 1 represents samples of 599 individuals from 23 different states in the U.S. in the age span 2-12. These samples were drawn in 1995. Table 2 represents over 600 individuals from six blood banks across the United States, focusing in the age span 20-69. These samples were drawn in 2000. 3M will send a final report on these analyses to the EPA in the near future. Table 1. Summary of Samples Drawn in 1995, Ages 2-12 C om pound PFOS C8Fl7S 03` PFHS C6F13C 0 2- PFOSAA rv~-xir' |7o0rW\2iv>ti\vr_'2*i i*5\; ' C H 2C 0 2- M 570 C 8F i7S 0 2N (C H .,)c h 2c o 2- PFOSA c 8f 17s o 2n - A verage 43.5 ppbw 15.0 ppb 4.4 ppb 3.4 ppb <LLOQ M edian 36.7 ppb 3.8 ppb 3.7 ppb 1.8 ppb <LLOQ 9 5 lh p e r c e n tile 90.2 ppb 71.3 ppb 10.4 ppb 12.5 ppb <LLOQ Range 6.7-515 ppb <LLOQ -712 ppb <LLOQ-23.8 ppb <LLOQ-48.0 ppb <LLOQ M556 CgFl7S 02NHc h 2c o 2- 3.0 ppb 2.5 ppb 7.3 ppb <LLOQ-19.1 ppb PFOA C7Fi5C 02- 5.6 ppb 5.1 ppb l 0 2 PPb _________ <LLOQ-56.1 ppb (a) ppb is parts per billion; (b)<LLOQ is less than the lower limit of quantification Table 2. Summary of Blood Bank Samples Drawn in 2000, Focusing on Ages 20-69 C om pound PFOS C8F17S 0 3` PFHS C6F,3C 02- A verage 43.7 ppb 2.9 ppb M edian 35.8 ppb 1.6 ppb 9 5 th p e r c e n tile 90.5 ppb 9.6 ppb PFOSAA C 8F ,7S 0 2N ( C 2H 5)c h 2c o 2- M 570 C 8F 17S 0 2N ( C F I i )C H 2C 0 2' PFOSA c 8f I7s o 2n M556 c 8f I7s o 2n h c h 2c o 2PFOA C7Fl5C 0 2- 3.0 ppb 18 ppb <LLOQ <LLOQ 5.6 ppb 1.4 ppb 0.9 ppb <LLOQ <LLOQ 4.7 ppb 7.6 ppb 5.3 ppb <LLOQ <LLOQ 12.9 ppb Range <LL.O Q -1656 ppb < L L O Q -66.3 ppb < L L O Q _60,1 ppb < L L O Q _19.0 ppb <LLOQ <LLO Q -12 9 ppb < L L O Q -52.3 ppb & E P A -O T S 000811817Q 10: \ h D0Dailfll?tJ I w Section 8(e) Coordinator May 15,2001 Page 2 Please contact me at 651-733-5181 for additional questions relative to the above analyses. Sincerely, Larry R. Zobel, MD MPH Staff Vice President & Medical Director 3M Medical Department12 (1) Letter to TSCA 8(e) Co-ordinator, May 15, 1998 (2) Perfluorooctane Sulfonate: Current Summary of Human Sera and Toxicology, January 21, 1999